Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Biocept Inc BIOCQ

Healthcare Medical Instruments & Supplies
Biocept, Inc. is a molecular diagnostics company with commercialized assays for patients with carcinomas or melanomas. The Company has developed a patented methodology to isolate cancer material that is shed from the primary tumor, such as CSF tumor cells (CSF-TCs) and cell-free DNA (cfDNA). As such, it is a commercial provider of testing services designed to enable clinicians to rapidly detect and monitor cancer biomarkers from a cerebrospinal fluid sample. The Company operates a clinical laboratory and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. The assays the Company offers are classified as laboratory developed tests (LDT) under the CLIA regulations. The Company’s assays, performed on cerebral spinal fluid, have the potential to provide more contemporaneous information on the characteristics of a patient’s disease.


GREY:BIOCQ - Post by User

Biocept Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(434)
•••
  • IseneschalX
Post by Iseneschalon Oct 25, 2023 10:36am
497 Views
Post# 35699990

BIOC....Delisted from NASDAQ this a.m....

BIOC....Delisted from NASDAQ this a.m....Now BIOCQ

Surprise surprise.....Just another "Curveball" thrown at the unsuspecting


Shareholders will be the last to know

This is a perfect example why you should never marry these Chitco's
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities